Felodipine

Identification

Name

Felodipine

Accession Number

DB01023  (APRD00374)

Type

Small Molecule

Groups

Approved, Investigational

Description

Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension.

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB01023 (Felodipine)

×

Close

Synonyms

• (+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
• 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate
• 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester
• Felodipina
• Felodipine
• Felodipinum

Product Images

PreviousNext

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Felodipineextended-release Tablets	Tablet, extended release	10 mg/1	Oral	Ranbaxy Inc.	2008-09-10	Not applicable
Felodipineextended-release Tablets	Tablet, extended release	5 mg/1	Oral	Ranbaxy Inc.	2008-09-10	Not applicable
Felodipineextended-release Tablets	Tablet, extended release	2.5 mg/1	Oral	Ranbaxy Inc.	2008-09-10	Not applicable
Plendil	Tablet, extended release	2.5 mg/1	Oral	Astra Zeneca Lp	1994-10-04	2016-11-04
Plendil	Tablet, extended release	10 mg/1	Oral	Astra Zeneca Lp	1991-09-16	2016-11-04
Plendil	Tablet, extended release	5 mg/1	Oral	Astra Zeneca Lp	1991-09-16	2016-11-04
Plendil	Tablet, extended release	10 mg/1	Oral	bryant ranch prepack	1991-09-16	Not applicable
Plendil 10 mg	Tablet, extended release	10 mg	Oral	Astra Zeneca	1992-12-31	Not applicable
Plendil 2.5 mg	Tablet, extended release	2.5 mg	Oral	Astra Zeneca	1994-12-31	Not applicable
Plendil 5 mg	Tablet, extended release	5 mg	Oral	Astra Zeneca	1992-12-31	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-felodipine	Tablet, extended release	5 mg	Oral	Apotex Corporation	2016-04-22	Not applicable
Apo-felodipine	Tablet, extended release	2.5 mg	Oral	Apotex Corporation	2016-04-22	Not applicable
Apo-felodipine	Tablet, extended release	10 mg	Oral	Apotex Corporation	2016-04-22	Not applicable
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Glenmark Pharmaceuticals Inc.,Usa	2010-12-20	Not applicable
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Jubilant Cadista Pharmaceuticals Inc.	2016-08-19	Not applicable
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Physicians Total Care, Inc.	2005-03-22	Not applicable
Felodipine	Tablet, extended release	5 mg/1	Oral	Qualitest	2011-12-15	Not applicable
Felodipine	Tablet, extended release	10 mg/1	Oral	A S Medication Solutions	2011-11-28	2017-06-20
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Av Kare, Inc.	2014-03-31	2016-01-15
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2004-11-02	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Altace Plus Felodipine 2.5mg + 2.5mg	Felodipine (2.5 mg) + Ramipril (2.5 mg)	Tablet	Oral	Sanofi Aventis	2006-06-27	2012-10-10
Altace Plus Felodipine 5mg + 5mg	Felodipine (5 mg) + Ramipril (5 mg)	Tablet	Oral	Sanofi Aventis	2006-06-27	2012-10-15

International/Other Brands

Felodur ER / Felogard / Penedil / Plendil Depottab (AstraZeneca) / Plendil ER (AstraZeneca) / Plendil Retard (AstraZeneca) / Splendil

Categories

• ACE Inhibitors and Calcium Channel Blockers
• Agents Acting on the Renin-Angiotensin System
• Anti-Arrhythmia Agents
• Antihypertensive Agents
• Calcium Channel Blockers
• Calcium Channel Blockers (Dihydropyridine)
• Cardiovascular Agents
• Cardiovascular System
• Combined Inhibitors of CYP3A4 and P-glycoprotein
• CYP3A Substrates (Sensitive)
• Cytochrome P-450 CYP2C8 Inhibitors
• Cytochrome P-450 CYP2C8 Inhibitors (moderate)
• Cytochrome P-450 CYP2C9 Inhibitors
• Cytochrome P-450 CYP2D6 Inhibitors
• Cytochrome P-450 CYP2D6 Inhibitors (weak)
• Cytochrome P-450 CYP3A Inhibitors
• Cytochrome P-450 CYP3A4 Inhibitors
• Cytochrome P-450 CYP3A4 Substrates
• Cytochrome P-450 CYP3A5 Substrates
• Cytochrome P-450 CYP3A7 Substrates
• Cytochrome P-450 Enzyme Inhibitors
• Dihydropyridines
• Hypotensive Agents
• Membrane Transport Modulators
• P-glycoprotein/ABCB1 Inhibitors
• Pyridines
• Vasodilator Agents

UNII

OL961R6O2C

CAS number

72509-76-3

Weight

Average: 384.254
Monoisotopic: 383.069113515

Chemical Formula

C₁₈H₁₉Cl₂NO₄

InChI Key

RZTAMFZIAATZDJ-UHFFFAOYSA-N

InChI

InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3

IUPAC Name

3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

SMILES

CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC

Pharmacology

Indication

For the treatment of mild to moderate essential hypertension.

Structured Indications

• High Blood Pressure (Hypertension)

Pharmacodynamics

Felodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction; however, some studies have shown that felodipine also binds to and inhibits T-type calcium channels. T-type calcium channels are most commonly found on neurons, cells with pacemaker activity and on osteocytes. The pharmacologic significance of T-type calcium channel blockade is unknown. Felodipine also binds to calmodulin and inhibits calmodulin-dependent calcium release from the sarcoplasmic reticulum. The effect of this interaction appears to be minor. Another study demonstrated that felodipine attenuates the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) by binding to the PDE-1B1 and PDE-1A2 enzyme subunits. CaMPDE is one of the key enzymes involved in cyclic nucleotides and calcium second messenger systems. Felodipine also acts as an antagonist to the mineralcorticoid receptor by competing with aldosterone for binding and blocking aldosterone-induced coactivator recruitment of the mineralcorticoid receptor. Felodipine is able to bind to skeletal and cardiac muscle isoforms of troponin C, one of the key regulatory proteins in muscle contraction. Though felodipine exhibits binding to many endogenous molecules, its vasodilatory effects are still thought to be brought about primarily through inhibition of voltage-gated L-type calcium channels. Similar to other DHP CCBs, felodipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives felodipine additional arterial selectivity. At therapeutic sub-toxic concentrations, felodipine has little effect on cardiac myocytes and conduction cells.

Mechanism of action

Felodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels. It reversibly competes against nitrendipine and other DHP CCBs for DHP binding sites in vascular smooth muscle and cultured rabbit atrial cells. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of felodipine result in an overall decrease in blood pressure. Felodipine may be used to treat mild to moderate essential hypertension.

Target	Actions	Organism
AVoltage-dependent L-type calcium channel subunit alpha-1C	inhibitor	Human
AVoltage-dependent calcium channel subunit alpha-2/delta-1	inhibitor	Human
AVoltage-dependent L-type calcium channel subunit beta-2	inhibitor	Human
AVoltage-dependent L-type calcium channel subunit alpha-1D	inhibitor	Human
AVoltage-dependent L-type calcium channel subunit alpha-1S	inhibitor	Human
UVoltage-dependent T-type calcium channel subunit alpha-1H	inhibitor	Human
UVoltage-dependent calcium channel subunit alpha-2/delta-2	inhibitor	Human
UCalmodulin	other	Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	inhibitor	Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	inhibitor	Human
UMineralocorticoid receptor	antagonist	Human
UTroponin C, skeletal muscle	other	Human
UTroponin C, slow skeletal and cardiac muscles	other	Human

Absorption

Is completely absorbed from the gastrointestinal tract; however, extensive first-pass metabolism through the portal circulation results in a low systemic availability of 15%. Bioavailability is unaffected by food.

Volume of distribution

• 10 L/kg

Protein binding

99%, primarily to the albumin fraction.

Metabolism

Hepatic metabolism primarily via cytochrome P450 3A4. Six metabolites with no appreciable vasodilatory effects have been identified.

• Felodipine
  dehydrofelodipine

Route of elimination

Although higher concentrations of the metabolites are present in the plasma due to decreased urinary excretion, these are inactive. Animal studies have demonstrated that felodipine crosses the blood-brain barrier and the placenta.

Half life

17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.

Clearance

• 0.8 L/min [Young healthy subjects]

Toxicity

Symptoms of overdose include excessive peripheral vasodilation with marked hypotension and possibly bradycardia. Oral rat LD₅₀ is 1050 mg/kg.

Affected organisms

• Humans and other mammals

Pathways

Pathway	Category
Felodipine Metabolism Pathway	Drug metabolism
Felodipine Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2-HYDROXY-1,4-NAPHTHOQUINONE	The therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Felodipine.	Experimental
2-mercaptobenzothiazole	The therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Felodipine.	Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Felodipine.	Experimental
Acebutolol	Felodipine may increase the hypotensive activities of Acebutolol.	Approved, Investigational
Acemetacin	The therapeutic efficacy of Felodipine can be decreased when used in combination with Acemetacin.	Approved, Experimental, Investigational
Acetaminophen	The metabolism of Acetaminophen can be decreased when combined with Felodipine.	Approved
Acetylsalicylic acid	The metabolism of Acetylsalicylic acid can be decreased when combined with Felodipine.	Approved, Vet Approved
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Felodipine.	Approved
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Felodipine.	Approved
Alfuzosin	Alfuzosin may increase the hypotensive activities of Felodipine.	Approved, Investigational
Aliskiren	Felodipine may increase the hypotensive activities of Aliskiren.	Approved, Investigational
Almotriptan	The metabolism of Almotriptan can be decreased when combined with Felodipine.	Approved, Investigational
Alprenolol	Alprenolol may increase the hypotensive activities of Felodipine.	Approved, Withdrawn
Ambrisentan	Felodipine may increase the hypotensive activities of Ambrisentan.	Approved, Investigational
Amifostine	Felodipine may increase the hypotensive activities of Amifostine.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Amiloride is combined with Felodipine.	Approved
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Felodipine.	Approved, Withdrawn
Amiodarone	The metabolism of Felodipine can be decreased when combined with Amiodarone.	Approved, Investigational
Amitriptyline	The metabolism of Amitriptyline can be decreased when combined with Felodipine.	Approved
Amlodipine	Amlodipine may increase the hypotensive activities of Felodipine.	Approved
Amobarbital	The metabolism of Felodipine can be increased when combined with Amobarbital.	Approved, Illicit
Amodiaquine	The serum concentration of Amodiaquine can be increased when it is combined with Felodipine.	Approved, Investigational
Amodiaquine	The metabolism of Amodiaquine can be decreased when combined with Felodipine.	Approved, Investigational
Amorolfine	The therapeutic efficacy of Amorolfine can be increased when used in combination with Felodipine.	Approved, Investigational
Amphetamine	Amphetamine may increase the hypotensive activities of Felodipine.	Approved, Illicit, Investigational
Amphotericin B	The risk or severity of adverse effects can be increased when Amphotericin B is combined with Felodipine.	Approved, Investigational
Amprenavir	The metabolism of Amprenavir can be decreased when combined with Felodipine.	Approved, Investigational
Amyl Nitrite	The risk or severity of adverse effects can be increased when Felodipine is combined with Amyl Nitrite.	Approved
Anidulafungin	The therapeutic efficacy of Anidulafungin can be increased when used in combination with Felodipine.	Approved, Investigational
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Felodipine.	Approved, Investigational
Apalutamide	The serum concentration of Felodipine can be decreased when it is combined with Apalutamide.	Approved, Investigational
Apixaban	The metabolism of Apixaban can be decreased when combined with Felodipine.	Approved
Apomorphine	The risk or severity of adverse effects can be increased when Apomorphine is combined with Felodipine.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Apraclonidine is combined with Felodipine.	Approved
Aprepitant	The serum concentration of Felodipine can be increased when it is combined with Aprepitant.	Approved, Investigational
Aripiprazole	Aripiprazole may increase the hypotensive activities of Felodipine.	Approved, Investigational
Arotinolol	The risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Felodipine.	Investigational
Arsenic trioxide	The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Felodipine.	Approved, Investigational
Artemether	The therapeutic efficacy of Artemether can be increased when used in combination with Felodipine.	Approved
Asunaprevir	The serum concentration of Asunaprevir can be increased when it is combined with Felodipine.	Approved, Investigational, Withdrawn
Atazanavir	The metabolism of Felodipine can be decreased when combined with Atazanavir.	Approved, Investigational
Atenolol	Atenolol may increase the hypotensive activities of Felodipine.	Approved
Atomoxetine	The metabolism of Felodipine can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The risk or severity of adverse effects can be increased when Felodipine is combined with Atorvastatin.	Approved
Avanafil	Avanafil may increase the antihypertensive activities of Felodipine.	Approved
Azelastine	The metabolism of Azelastine can be decreased when combined with Felodipine.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Felodipine is combined with Azilsartan medoxomil.	Approved, Investigational
Bafilomycin A1	The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Felodipine.	Experimental
Barbexaclone	The metabolism of Felodipine can be increased when combined with Barbexaclone.	Experimental
Barbital	The metabolism of Felodipine can be increased when combined with Barbital.	Illicit
Barnidipine	Felodipine may increase the antihypertensive activities of Barnidipine.	Approved
Benazepril	Benazepril may increase the hypotensive activities of Felodipine.	Approved, Investigational
Bendroflumethiazide	Bendroflumethiazide may increase the hypotensive activities of Felodipine.	Approved
Benmoxin	Benmoxin may increase the hypotensive activities of Felodipine.	Withdrawn
Benzoic Acid	The therapeutic efficacy of Benzoic Acid can be increased when used in combination with Felodipine.	Approved, Investigational
Benzyl alcohol	The metabolism of Benzyl alcohol can be decreased when combined with Felodipine.	Approved
Bepridil	Felodipine may increase the hypotensive activities of Bepridil.	Approved, Withdrawn
Beraprost	The metabolism of Beraprost can be decreased when combined with Felodipine.	Investigational
Betaxolol	Betaxolol may increase the hypotensive activities of Felodipine.	Approved, Investigational
Bethanidine	Bethanidine may increase the hypotensive activities of Felodipine.	Approved
Bietaserpine	Bietaserpine may increase the hypotensive activities of Felodipine.	Experimental
Bifonazole	The therapeutic efficacy of Bifonazole can be increased when used in combination with Felodipine.	Approved, Investigational
Bimatoprost	Bimatoprost may increase the hypotensive activities of Felodipine.	Approved, Investigational
Bisoprolol	Bisoprolol may increase the hypotensive activities of Felodipine.	Approved
Boceprevir	The metabolism of Felodipine can be decreased when combined with Boceprevir.	Approved, Withdrawn
Bortezomib	The metabolism of Felodipine can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Felodipine can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Felodipine.	Approved
BQ-123	Felodipine may increase the hypotensive activities of BQ-123.	Investigational
Brefeldin A	The therapeutic efficacy of Brefeldin A can be increased when used in combination with Felodipine.	Experimental
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Felodipine.	Approved, Investigational
Bretylium	Felodipine may increase the hypotensive activities of Bretylium.	Approved
Brigatinib	The serum concentration of Felodipine can be decreased when it is combined with Brigatinib.	Approved, Investigational
Brimonidine	Brimonidine may increase the antihypertensive activities of Felodipine.	Approved
Brofaromine	Brofaromine may increase the hypotensive activities of Felodipine.	Experimental
Bromocriptine	The risk or severity of adverse effects can be increased when Bromocriptine is combined with Felodipine.	Approved, Investigational
Brompheniramine	The metabolism of Brompheniramine can be decreased when combined with Felodipine.	Approved
Bucindolol	The risk or severity of hypotension can be increased when Bucindolol is combined with Felodipine.	Investigational
Bumetanide	The risk or severity of adverse effects can be increased when Bumetanide is combined with Felodipine.	Approved
Bunazosin	The risk or severity of hypotension can be increased when Bunazosin is combined with Felodipine.	Investigational
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Felodipine.	Approved, Investigational
Bupranolol	Felodipine may increase the hypotensive activities of Bupranolol.	Approved
Buprenorphine	The metabolism of Buprenorphine can be decreased when combined with Felodipine.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The metabolism of Bupropion can be decreased when combined with Felodipine.	Approved
Butenafine	The therapeutic efficacy of Butenafine can be increased when used in combination with Felodipine.	Approved
Butoconazole	The therapeutic efficacy of Butoconazole can be increased when used in combination with Felodipine.	Approved
Cabazitaxel	The metabolism of Cabazitaxel can be decreased when combined with Felodipine.	Approved
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Felodipine.	Approved
Cadralazine	Cadralazine may increase the hypotensive activities of Felodipine.	Experimental
Cafedrine	Felodipine may increase the hypotensive activities of Cafedrine.	Investigational
Caffeine	The metabolism of Caffeine can be decreased when combined with Felodipine.	Approved
Calcium Acetate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Acetate.	Approved, Investigational
Calcium Chloride	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Chloride.	Approved
Calcium Citrate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Citrate.	Approved
Calcium glubionate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium glubionate.	Approved
Calcium Gluceptate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Gluceptate.	Approved
Calcium gluconate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium gluconate.	Approved, Vet Approved
Calcium lactate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium lactate.	Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium lactate gluconate.	Experimental
Calcium levulinate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium levulinate.	Approved, Experimental
Calcium pangamate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium pangamate.	Experimental
Calcium Phosphate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Phosphate.	Approved
Canagliflozin	The risk or severity of adverse effects can be increased when Felodipine is combined with Canagliflozin.	Approved
Candesartan	Felodipine may increase the hypotensive activities of Candesartan.	Experimental
Candesartan cilexetil	Candesartan cilexetil may increase the hypotensive activities of Felodipine.	Approved
Candicidin	The therapeutic efficacy of Candicidin can be increased when used in combination with Felodipine.	Withdrawn
Candoxatril	Candoxatril may increase the hypotensive activities of Felodipine.	Experimental
Capric acid	The therapeutic efficacy of Capric acid can be increased when used in combination with Felodipine.	Experimental
Captopril	Felodipine may increase the hypotensive activities of Captopril.	Approved
Carbamazepine	The metabolism of Felodipine can be increased when combined with Carbamazepine.	Approved, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Carbetocin is combined with Felodipine.	Approved, Investigational
Carbinoxamine	The metabolism of Carbinoxamine can be decreased when combined with Felodipine.	Approved
Caroxazone	Caroxazone may increase the hypotensive activities of Felodipine.	Withdrawn
Carteolol	Carteolol may increase the hypotensive activities of Felodipine.	Approved
Carvedilol	Felodipine may increase the hypotensive activities of Carvedilol.	Approved, Investigational
Casein	The therapeutic efficacy of Felodipine can be decreased when used in combination with Casein.	Approved
Caspofungin	The therapeutic efficacy of Caspofungin can be increased when used in combination with Felodipine.	Approved
Celiprolol	Felodipine may increase the hypotensive activities of Celiprolol.	Approved, Investigational
Ceritinib	The serum concentration of Felodipine can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Felodipine.	Approved, Withdrawn
Cerulenin	The therapeutic efficacy of Cerulenin can be increased when used in combination with Felodipine.	Approved
Chloroquine	The metabolism of Chloroquine can be decreased when combined with Felodipine.	Approved, Investigational, Vet Approved
Chlorothiazide	Chlorothiazide may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Chloroxine	The therapeutic efficacy of Chloroxine can be increased when used in combination with Felodipine.	Approved
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Felodipine.	Approved, Investigational, Vet Approved
Chlorthalidone	Chlorthalidone may increase the hypotensive activities of Felodipine.	Approved
Cicletanine	Felodipine may increase the hypotensive activities of Cicletanine.	Investigational
Ciclopirox	The therapeutic efficacy of Ciclopirox can be increased when used in combination with Felodipine.	Approved, Investigational
Cilazapril	Felodipine may increase the hypotensive activities of Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Cilnidipine is combined with Felodipine.	Approved, Investigational
Cimetidine	The serum concentration of Felodipine can be increased when it is combined with Cimetidine.	Approved, Investigational
Cisapride	The metabolism of Cisapride can be decreased when combined with Felodipine.	Approved, Investigational, Withdrawn
Clarithromycin	The metabolism of Felodipine can be decreased when combined with Clarithromycin.	Approved
Clemastine	The metabolism of Felodipine can be decreased when combined with Clemastine.	Approved, Investigational
Clevidipine	The risk or severity of adverse effects can be increased when Felodipine is combined with Clevidipine.	Approved, Investigational
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Felodipine.	Approved, Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Clomipramine is combined with Felodipine.	Approved, Investigational, Vet Approved
Clonidine	Clonidine may increase the hypotensive activities of Felodipine.	Approved
Clopidogrel	The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Felodipine.	Approved
Cloranolol	Felodipine may increase the hypotensive activities of Cloranolol.	Experimental
Clotrimazole	The metabolism of Felodipine can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The metabolism of Clozapine can be decreased when combined with Felodipine.	Approved
Cobicistat	The metabolism of Felodipine can be decreased when combined with Cobicistat.	Approved
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Felodipine.	Approved
Conivaptan	The serum concentration of Conivaptan can be increased when it is combined with Felodipine.	Approved, Investigational
Cordycepin	The therapeutic efficacy of Cordycepin can be increased when used in combination with Felodipine.	Investigational
Crizotinib	The metabolism of Felodipine can be decreased when combined with Crizotinib.	Approved
Cryptenamine	Cryptenamine may increase the hypotensive activities of Felodipine.	Approved
Cyclopenthiazide	Felodipine may increase the hypotensive activities of Cyclopenthiazide.	Experimental
Cyclophosphamide	The metabolism of Cyclophosphamide can be decreased when combined with Felodipine.	Approved, Investigational
Cyclosporine	The metabolism of Felodipine can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyclothiazide	Cyclothiazide may increase the hypotensive activities of Felodipine.	Approved
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Felodipine.	Approved
Dabrafenib	The serum concentration of Felodipine can be decreased when it is combined with Dabrafenib.	Approved, Investigational
Dapagliflozin	The risk or severity of adverse effects can be increased when Felodipine is combined with Dapagliflozin.	Approved
Dapsone	The metabolism of Dapsone can be decreased when combined with Felodipine.	Approved, Investigational
Darunavir	The metabolism of Felodipine can be decreased when combined with Darunavir.	Approved
Dasabuvir	The metabolism of Dasabuvir can be decreased when combined with Felodipine.	Approved
Dasatinib	The serum concentration of Felodipine can be increased when it is combined with Dasatinib.	Approved, Investigational
Debrisoquin	Debrisoquin may increase the hypotensive activities of Felodipine.	Approved, Investigational
Deferasirox	The serum concentration of Felodipine can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delapril	Felodipine may increase the hypotensive activities of Delapril.	Experimental
Delavirdine	The metabolism of Felodipine can be decreased when combined with Delavirdine.	Approved
Deserpidine	Felodipine may increase the hypotensive activities of Deserpidine.	Approved
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Felodipine.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Felodipine.	Approved, Vet Approved
Dextromethorphan	The metabolism of Dextromethorphan can be decreased when combined with Felodipine.	Approved
Diazepam	The metabolism of Diazepam can be decreased when combined with Felodipine.	Approved, Illicit, Investigational, Vet Approved
Diazoxide	Diazoxide may increase the hypotensive activities of Felodipine.	Approved
Dichlorophene	The therapeutic efficacy of Dichlorophene can be increased when used in combination with Felodipine.	Vet Approved
Diclofenac	The metabolism of Diclofenac can be decreased when combined with Felodipine.	Approved, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Felodipine is combined with Diclofenamide.	Approved, Investigational
Diethylnorspermine	Felodipine may increase the hypotensive activities of Diethylnorspermine.	Investigational
Dihydralazine	Dihydralazine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Dihydroergocornine	The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Felodipine.	Approved
Dihydroergocristine	The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Felodipine.	Approved, Experimental
Dihydroergocryptine	The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Felodipine.	Experimental
Dihydroergotamine	The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Felodipine.	Approved, Investigational
Diltiazem	The metabolism of Felodipine can be decreased when combined with Diltiazem.	Approved, Investigational
Dinutuximab	The risk or severity of adverse effects can be increased when Felodipine is combined with Dinutuximab.	Approved, Investigational
Dipyridamole	The risk or severity of adverse effects can be increased when Dipyridamole is combined with Felodipine.	Approved
Domperidone	The metabolism of Domperidone can be decreased when combined with Felodipine.	Approved, Investigational, Vet Approved
Dorzolamide	Dorzolamide may increase the hypotensive activities of Felodipine.	Approved
Doxazosin	Doxazosin may increase the hypotensive activities of Felodipine.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Felodipine.	Approved, Investigational
Doxycycline	The metabolism of Felodipine can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronedarone	The metabolism of Felodipine can be decreased when combined with Dronedarone.	Approved
Duloxetine	Felodipine may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Econazole	The therapeutic efficacy of Econazole can be increased when used in combination with Felodipine.	Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Felodipine.	Approved
Efavirenz	The serum concentration of Felodipine can be decreased when it is combined with Efavirenz.	Approved, Investigational
Efinaconazole	The therapeutic efficacy of Efinaconazole can be increased when used in combination with Felodipine.	Approved
Efonidipine	Felodipine may increase the hypotensive activities of Efonidipine.	Approved, Investigational
Eltrombopag	The metabolism of Eltrombopag can be decreased when combined with Felodipine.	Approved
Empagliflozin	The risk or severity of adverse effects can be increased when Felodipine is combined with Empagliflozin.	Approved
Enalapril	Enalapril may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Enalaprilat	Felodipine may increase the hypotensive activities of Enalaprilat.	Approved
Enasidenib	The metabolism of Enasidenib can be decreased when combined with Felodipine.	Approved, Investigational
Endralazine	Endralazine may increase the hypotensive activities of Felodipine.	Experimental
Enzalutamide	The serum concentration of Felodipine can be decreased when it is combined with Enzalutamide.	Approved
Epanolol	Felodipine may increase the hypotensive activities of Epanolol.	Experimental
Eplerenone	The risk or severity of adverse effects can be increased when Eplerenone is combined with Felodipine.	Approved
Epoprostenol	Felodipine may increase the hypotensive activities of Epoprostenol.	Approved
Eprosartan	Eprosartan may increase the hypotensive activities of Felodipine.	Approved
Ergonovine	The risk or severity of adverse effects can be increased when Ergonovine is combined with Felodipine.	Approved
Ergotamine	The risk or severity of adverse effects can be increased when Ergotamine is combined with Felodipine.	Approved
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Felodipine.	Approved, Investigational
Erythromycin	The metabolism of Felodipine can be decreased when combined with Erythromycin.	Approved, Investigational, Vet Approved
Esmolol	The risk or severity of adverse effects can be increased when Esmolol is combined with Felodipine.	Approved
Estradiol	The metabolism of Estradiol can be decreased when combined with Felodipine.	Approved, Investigational, Vet Approved
Estradiol acetate	The metabolism of Estradiol acetate can be decreased when combined with Felodipine.	Approved, Investigational, Vet Approved
Estradiol benzoate	The metabolism of Estradiol benzoate can be decreased when combined with Felodipine.	Approved, Investigational, Vet Approved
Estradiol cypionate	The metabolism of Estradiol cypionate can be decreased when combined with Felodipine.	Approved, Investigational, Vet Approved
Estradiol dienanthate	The metabolism of Estradiol dienanthate can be decreased when combined with Felodipine.	Approved, Investigational, Vet Approved
Estradiol valerate	The metabolism of Estradiol valerate can be decreased when combined with Felodipine.	Approved, Investigational, Vet Approved
Eszopiclone	The metabolism of Eszopiclone can be decreased when combined with Felodipine.	Approved, Investigational
Etacrynic acid	The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Felodipine.	Approved, Investigational
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Felodipine.	Approved
Fenoldopam	Fenoldopam may increase the hypotensive activities of Felodipine.	Approved
Fenticonazole	The therapeutic efficacy of Fenticonazole can be increased when used in combination with Felodipine.	Experimental
Ferulic acid	Felodipine may increase the hypotensive activities of Ferulic acid.	Experimental
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Felodipine.	Approved
Fimasartan	The risk or severity of adverse effects can be increased when Fimasartan is combined with Felodipine.	Approved, Investigational
Fluconazole	The serum concentration of Felodipine can be increased when it is combined with Fluconazole.	Approved, Investigational
Flucytosine	The therapeutic efficacy of Flucytosine can be increased when used in combination with Felodipine.	Approved, Investigational
Fluorouracil	The metabolism of Fluorouracil can be decreased when combined with Felodipine.	Approved
Flutrimazole	The therapeutic efficacy of Flutrimazole can be increased when used in combination with Felodipine.	Experimental
Fluvastatin	The serum concentration of Fluvastatin can be increased when it is combined with Felodipine.	Approved
Fluvoxamine	The metabolism of Felodipine can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Felodipine can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Felodipine can be increased when it is combined with Fosaprepitant.	Approved
Fosinopril	Fosinopril may increase the hypotensive activities of Felodipine.	Approved
Fosphenytoin	The metabolism of Felodipine can be increased when combined with Fosphenytoin.	Approved, Investigational
Furazolidone	Furazolidone may increase the hypotensive activities of Felodipine.	Approved, Investigational, Vet Approved
Furosemide	The risk or severity of adverse effects can be increased when Furosemide is combined with Felodipine.	Approved, Vet Approved
Fusidic Acid	The serum concentration of Felodipine can be increased when it is combined with Fusidic Acid.	Approved, Investigational
Glyphosate	The therapeutic efficacy of Glyphosate can be increased when used in combination with Felodipine.	Experimental
Griseofulvin	The therapeutic efficacy of Griseofulvin can be increased when used in combination with Felodipine.	Approved, Investigational, Vet Approved
Guanabenz	Guanabenz may increase the hypotensive activities of Felodipine.	Approved, Investigational
Guanadrel	Guanadrel may increase the hypotensive activities of Felodipine.	Approved
Guanazodine	Felodipine may increase the hypotensive activities of Guanazodine.	Experimental
Guanethidine	Felodipine may increase the hypotensive activities of Guanethidine.	Approved
Guanfacine	Guanfacine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Guanoclor	Felodipine may increase the hypotensive activities of Guanoclor.	Experimental
Guanoxabenz	Felodipine may increase the hypotensive activities of Guanoxabenz.	Experimental
Guanoxan	Felodipine may increase the hypotensive activities of Guanoxan.	Experimental
Hachimycin	The therapeutic efficacy of Hachimycin can be increased when used in combination with Felodipine.	Experimental
Halofantrine	The metabolism of Halofantrine can be decreased when combined with Felodipine.	Approved
Haloprogin	The therapeutic efficacy of Haloprogin can be increased when used in combination with Felodipine.	Approved, Withdrawn
Halothane	The risk or severity of adverse effects can be increased when Halothane is combined with Felodipine.	Approved, Vet Approved
Harmaline	Harmaline may increase the hypotensive activities of Felodipine.	Experimental
Hexamethonium	Felodipine may increase the hypotensive activities of Hexamethonium.	Experimental
Hexetidine	The therapeutic efficacy of Hexetidine can be increased when used in combination with Felodipine.	Approved, Investigational
Hexobarbital	The metabolism of Felodipine can be increased when combined with Hexobarbital.	Approved
Hydracarbazine	Hydracarbazine may increase the hypotensive activities of Felodipine.	Experimental
Hydralazine	Hydralazine may increase the hypotensive activities of Felodipine.	Approved
Hydrochlorothiazide	Hydrochlorothiazide may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Hydroflumethiazide	Hydroflumethiazide may increase the hypotensive activities of Felodipine.	Approved, Investigational
Ibrutinib	The serum concentration of Ibrutinib can be increased when it is combined with Felodipine.	Approved
Ibuprofen	The metabolism of Ibuprofen can be decreased when combined with Felodipine.	Approved
Idelalisib	The serum concentration of Felodipine can be increased when it is combined with Idelalisib.	Approved
Ifosfamide	The metabolism of Ifosfamide can be decreased when combined with Felodipine.	Approved
Iloprost	The risk or severity of adverse effects can be increased when Iloprost is combined with Felodipine.	Approved, Investigational
Imatinib	The metabolism of Felodipine can be decreased when combined with Imatinib.	Approved
Imidapril	Felodipine may increase the hypotensive activities of Imidapril.	Investigational
Imipramine	The risk or severity of adverse effects can be increased when Imipramine is combined with Felodipine.	Approved
Indapamide	Indapamide may increase the hypotensive activities of Felodipine.	Approved
Indenolol	Felodipine may increase the hypotensive activities of Indenolol.	Withdrawn
Indinavir	The metabolism of Felodipine can be decreased when combined with Indinavir.	Approved
Indoramin	Indoramin may increase the hypotensive activities of Felodipine.	Withdrawn
Iproclozide	Iproclozide may increase the hypotensive activities of Felodipine.	Withdrawn
Iproniazid	Iproniazid may increase the hypotensive activities of Felodipine.	Withdrawn
Irbesartan	The metabolism of Irbesartan can be decreased when combined with Felodipine.	Approved, Investigational
Isavuconazole	The serum concentration of Felodipine can be increased when it is combined with Isavuconazole.	Approved, Investigational
Isavuconazonium	The metabolism of Felodipine can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isocarboxazid	Isocarboxazid may increase the hypotensive activities of Felodipine.	Approved
Isoconazole	The therapeutic efficacy of Isoconazole can be increased when used in combination with Felodipine.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Isoflurane is combined with Felodipine.	Approved, Vet Approved
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Felodipine.	Approved, Investigational
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Felodipine.	Approved
Isoxsuprine	The risk or severity of adverse effects can be increased when Felodipine is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	The metabolism of Felodipine can be decreased when combined with Isradipine.	Approved, Investigational
Itraconazole	The serum concentration of Felodipine can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Felodipine can be increased when it is combined with Ivacaftor.	Approved
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Felodipine.	Approved, Investigational
Ketamine	The metabolism of Ketamine can be decreased when combined with Felodipine.	Approved, Vet Approved
Ketanserin	Ketanserin may increase the hypotensive activities of Felodipine.	Investigational
Ketobemidone	The metabolism of Ketobemidone can be decreased when combined with Felodipine.	Approved, Investigational
Ketoconazole	The serum concentration of Felodipine can be increased when it is combined with Ketoconazole.	Approved, Investigational
Labetalol	Labetalol may increase the hypotensive activities of Felodipine.	Approved
Lacidipine	Felodipine may increase the hypotensive activities of Lacidipine.	Approved, Investigational
Lansoprazole	The metabolism of Lansoprazole can be decreased when combined with Felodipine.	Approved, Investigational
Lapatinib	The metabolism of Lapatinib can be decreased when combined with Felodipine.	Approved, Investigational
Latanoprost	Latanoprost may increase the hypotensive activities of Felodipine.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Felodipine.	Approved
Lercanidipine	Lercanidipine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Levobunolol	The risk or severity of adverse effects can be increased when Felodipine is combined with Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Felodipine.	Approved, Investigational
Levodopa	Felodipine may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levomilnacipran	The metabolism of Levomilnacipran can be decreased when combined with Felodipine.	Approved, Investigational
Levosimendan	The risk or severity of adverse effects can be increased when Levosimendan is combined with Felodipine.	Approved, Investigational
Licofelone	The metabolism of Licofelone can be decreased when combined with Felodipine.	Investigational
Lidocaine	The metabolism of Lidocaine can be decreased when combined with Felodipine.	Approved, Vet Approved
Linsidomine	Felodipine may increase the hypotensive activities of Linsidomine.	Experimental
Lisinopril	Lisinopril may increase the hypotensive activities of Felodipine.	Approved, Investigational
Lisuride	The risk or severity of adverse effects can be increased when Lisuride is combined with Felodipine.	Approved, Investigational
Lofexidine	Felodipine may increase the hypotensive activities of Lofexidine.	Approved, Investigational
Loperamide	The metabolism of Loperamide can be decreased when combined with Felodipine.	Approved
Lopinavir	The metabolism of Felodipine can be decreased when combined with Lopinavir.	Approved
Loratadine	The metabolism of Loratadine can be decreased when combined with Felodipine.	Approved, Investigational
Lorpiprazole	The serum concentration of Felodipine can be increased when it is combined with Lorpiprazole.	Approved
Losartan	The metabolism of Losartan can be decreased when combined with Felodipine.	Approved
Lovastatin	The serum concentration of Lovastatin can be increased when it is combined with Felodipine.	Approved, Investigational
Luliconazole	The serum concentration of Felodipine can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The metabolism of Felodipine can be increased when combined with Lumacaftor.	Approved
Lysergic Acid Diethylamide	The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Felodipine.	Illicit, Investigational, Withdrawn
Macitentan	Felodipine may increase the hypotensive activities of Macitentan.	Approved
Magnesium hydroxide	The risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium hydroxide.	Approved, Investigational
Magnesium oxide	The risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium oxide.	Approved
Magnesium salicylate	The risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium salicylate.	Approved
Magnesium sulfate	The risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium sulfate.	Approved, Investigational, Vet Approved
Manidipine	Felodipine may increase the hypotensive activities of Manidipine.	Approved, Investigational
Mannitol	The risk or severity of adverse effects can be increased when Mannitol is combined with Felodipine.	Approved, Investigational
Mebanazine	Mebanazine may increase the hypotensive activities of Felodipine.	Withdrawn
Mecamylamine	Mecamylamine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Mefenamic acid	The metabolism of Mefenamic acid can be decreased when combined with Felodipine.	Approved
Melatonin	Melatonin may decrease the antihypertensive activities of Felodipine.	Approved, Nutraceutical, Vet Approved
Meloxicam	The metabolism of Meloxicam can be decreased when combined with Felodipine.	Approved, Vet Approved
Mepartricin	The therapeutic efficacy of Mepartricin can be increased when used in combination with Felodipine.	Experimental
Mephenytoin	The metabolism of Mephenytoin can be decreased when combined with Felodipine.	Investigational, Withdrawn
Metergoline	The risk or severity of adverse effects can be increased when Metergoline is combined with Felodipine.	Experimental
Methadone	The metabolism of Methadone can be decreased when combined with Felodipine.	Approved
Methazolamide	The risk or severity of adverse effects can be increased when Methazolamide is combined with Felodipine.	Approved
Methohexital	The metabolism of Felodipine can be increased when combined with Methohexital.	Approved
Methoserpidine	Felodipine may increase the hypotensive activities of Methoserpidine.	Experimental
Methyclothiazide	The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Felodipine.	Approved
Methyldopa	Methyldopa may increase the hypotensive activities of Felodipine.	Approved
Methylene blue	Methylene blue may increase the hypotensive activities of Felodipine.	Approved, Investigational
Methylergometrine	The risk or severity of adverse effects can be increased when Methylergometrine is combined with Felodipine.	Approved
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Felodipine.	Approved, Investigational
Methylphenobarbital	The metabolism of Felodipine can be increased when combined with Methylphenobarbital.	Approved
Methysergide	The risk or severity of adverse effects can be increased when Methysergide is combined with Felodipine.	Approved
Metipranolol	Felodipine may increase the hypotensive activities of Metipranolol.	Approved
Metolazone	Metolazone may increase the hypotensive activities of Felodipine.	Approved
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Felodipine.	Approved, Investigational
Metyrosine	Felodipine may increase the hypotensive activities of Metyrosine.	Approved
Mevastatin	The serum concentration of Mevastatin can be increased when it is combined with Felodipine.	Experimental
Mibefradil	Felodipine may increase the hypotensive activities of Mibefradil.	Investigational, Withdrawn
Micafungin	The therapeutic efficacy of Micafungin can be increased when used in combination with Felodipine.	Approved, Investigational
Miconazole	The therapeutic efficacy of Miconazole can be increased when used in combination with Felodipine.	Approved, Investigational, Vet Approved
Mifepristone	The serum concentration of Felodipine can be increased when it is combined with Mifepristone.	Approved, Investigational
Miltefosine	The therapeutic efficacy of Miltefosine can be increased when used in combination with Felodipine.	Approved, Investigational
Minaprine	Minaprine may increase the hypotensive activities of Felodipine.	Approved
Minoxidil	Minoxidil may increase the hypotensive activities of Felodipine.	Approved, Investigational
Mirodenafil	Mirodenafil may increase the antihypertensive activities of Felodipine.	Investigational
Mirtazapine	The metabolism of Mirtazapine can be decreased when combined with Felodipine.	Approved
Mitotane	The serum concentration of Felodipine can be decreased when it is combined with Mitotane.	Approved
Moclobemide	Moclobemide may increase the hypotensive activities of Felodipine.	Approved, Investigational
Moexipril	Moexipril may increase the hypotensive activities of Felodipine.	Approved
Molsidomine	Molsidomine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Monensin	The therapeutic efficacy of Monensin can be increased when used in combination with Felodipine.	Vet Approved
Morphine	The metabolism of Morphine can be decreased when combined with Felodipine.	Approved, Investigational
Moxonidine	Moxonidine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Muraglitazar	The metabolism of Muraglitazar can be decreased when combined with Felodipine.	Investigational
Muzolimine	Felodipine may increase the hypotensive activities of Muzolimine.	Experimental
Mycophenolate mofetil	The metabolism of Mycophenolate mofetil can be decreased when combined with Felodipine.	Approved, Investigational
Myxothiazol	The therapeutic efficacy of Myxothiazol can be increased when used in combination with Felodipine.	Experimental
Nabilone	The risk or severity of adverse effects can be increased when Nabilone is combined with Felodipine.	Approved, Investigational
Nadolol	Felodipine may increase the hypotensive activities of Nadolol.	Approved
Nafcillin	The therapeutic efficacy of Felodipine can be decreased when used in combination with Nafcillin.	Approved, Investigational
Naftifine	The therapeutic efficacy of Naftifine can be increased when used in combination with Felodipine.	Approved
Naftopidil	Felodipine may increase the hypotensive activities of Naftopidil.	Investigational
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Felodipine.	Approved
Naloxone	The metabolism of Naloxone can be decreased when combined with Felodipine.	Approved, Vet Approved
Naproxen	The metabolism of Naproxen can be decreased when combined with Felodipine.	Approved, Vet Approved
Natamycin	The therapeutic efficacy of Natamycin can be increased when used in combination with Felodipine.	Approved
Nebivolol	Felodipine may increase the hypotensive activities of Nebivolol.	Approved, Investigational
Nefazodone	The metabolism of Felodipine can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The metabolism of Felodipine can be decreased when combined with Nelfinavir.	Approved
Nesiritide	The risk or severity of adverse effects can be increased when Felodipine is combined with Nesiritide.	Approved, Investigational
Netupitant	The serum concentration of Felodipine can be increased when it is combined with Netupitant.	Approved, Investigational
Nevirapine	The metabolism of Felodipine can be increased when combined with Nevirapine.	Approved
Nialamide	Nialamide may increase the hypotensive activities of Felodipine.	Withdrawn
Nicardipine	The metabolism of Nicardipine can be decreased when combined with Felodipine.	Approved, Investigational
Nicergoline	The risk or severity of adverse effects can be increased when Nicergoline is combined with Felodipine.	Approved, Investigational
Nicorandil	Nicorandil may increase the hypotensive activities of Felodipine.	Approved, Investigational
Nicotine	The metabolism of Nicotine can be decreased when combined with Felodipine.	Approved
Nifedipine	The risk or severity of adverse effects can be increased when Felodipine is combined with Nifedipine.	Approved
Nifuratel	The therapeutic efficacy of Nifuratel can be increased when used in combination with Felodipine.	Experimental
Niguldipine	Felodipine may increase the hypotensive activities of Niguldipine.	Experimental
Nikkomycin Z	The therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Felodipine.	Investigational
Nilotinib	The metabolism of Felodipine can be decreased when combined with Nilotinib.	Approved, Investigational
Nilvadipine	Felodipine may increase the hypotensive activities of Nilvadipine.	Approved, Investigational
Nimodipine	Nimodipine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Felodipine.	Approved
Nisoldipine	Nisoldipine may increase the hypotensive activities of Felodipine.	Approved
Nitrendipine	Felodipine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Nitric Oxide	The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Felodipine.	Approved
Nitroglycerin	The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Felodipine.	Approved, Investigational
Nitroprusside	Felodipine may increase the hypotensive activities of Nitroprusside.	Approved, Investigational
Nitrous acid	The risk or severity of adverse effects can be increased when Nitrous acid is combined with Felodipine.	Approved, Investigational
Nitroxoline	The therapeutic efficacy of Nitroxoline can be increased when used in combination with Felodipine.	Approved
Nystatin	The therapeutic efficacy of Nystatin can be increased when used in combination with Felodipine.	Approved, Vet Approved
Obinutuzumab	Felodipine may increase the hypotensive activities of Obinutuzumab.	Approved, Investigational
Octamoxin	Octamoxin may increase the hypotensive activities of Felodipine.	Withdrawn
Odanacatib	The metabolism of Odanacatib can be decreased when combined with Felodipine.	Investigational
Olaparib	The metabolism of Felodipine can be decreased when combined with Olaparib.	Approved
Olmesartan	Olmesartan may increase the hypotensive activities of Felodipine.	Approved, Investigational
Olodaterol	The metabolism of Olodaterol can be decreased when combined with Felodipine.	Approved
Omapatrilat	Omapatrilat may increase the hypotensive activities of Felodipine.	Investigational
Ombitasvir	The metabolism of Ombitasvir can be decreased when combined with Felodipine.	Approved, Investigational
Omeprazole	The metabolism of Omeprazole can be decreased when combined with Felodipine.	Approved, Investigational, Vet Approved
Omoconazole	The therapeutic efficacy of Omoconazole can be increased when used in combination with Felodipine.	Experimental
Osimertinib	The serum concentration of Felodipine can be increased when it is combined with Osimertinib.	Approved
Oxiconazole	The therapeutic efficacy of Oxiconazole can be increased when used in combination with Felodipine.	Approved
Oxprenolol	Felodipine may increase the hypotensive activities of Oxprenolol.	Approved
Paclitaxel	The metabolism of Paclitaxel can be decreased when combined with Felodipine.	Approved, Vet Approved
Pafuramidine	The therapeutic efficacy of Pafuramidine can be increased when used in combination with Felodipine.	Investigational
Palbociclib	The serum concentration of Felodipine can be increased when it is combined with Palbociclib.	Approved, Investigational
Papaverine	The risk or severity of adverse effects can be increased when Felodipine is combined with Papaverine.	Approved, Investigational
Paramethadione	The metabolism of Paramethadione can be decreased when combined with Felodipine.	Approved
Pargyline	Pargyline may increase the hypotensive activities of Felodipine.	Approved
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Felodipine.	Approved
Penbutolol	Felodipine may increase the hypotensive activities of Penbutolol.	Approved, Investigational
Pentamidine	The metabolism of Pentamidine can be decreased when combined with Felodipine.	Approved, Investigational
Pentobarbital	The metabolism of Felodipine can be increased when combined with Pentobarbital.	Approved, Investigational, Vet Approved
Pentolinium	Felodipine may increase the hypotensive activities of Pentolinium.	Approved
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Felodipine.	Approved, Investigational
Pergolide	The risk or severity of adverse effects can be increased when Pergolide is combined with Felodipine.	Approved, Investigational, Vet Approved, Withdrawn
Perindopril	Perindopril may increase the hypotensive activities of Felodipine.	Approved
Perospirone	The metabolism of Perospirone can be decreased when combined with Felodipine.	Approved
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Felodipine.	Approved
Phenelzine	Phenelzine may increase the hypotensive activities of Felodipine.	Approved
Pheniprazine	Pheniprazine may increase the hypotensive activities of Felodipine.	Withdrawn
Phenobarbital	The metabolism of Felodipine can be increased when combined with Phenobarbital.	Approved, Investigational
Phenoxybenzamine	Phenoxybenzamine may increase the hypotensive activities of Felodipine.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypotensive activities of Felodipine.	Withdrawn
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Felodipine.	Approved, Investigational
Phentolamine	Phentolamine may increase the hypotensive activities of Felodipine.	Approved
Phenytoin	The metabolism of Felodipine can be increased when combined with Phenytoin.	Approved, Vet Approved
Pinacidil	Pinacidil may increase the hypotensive activities of Felodipine.	Approved
Pindolol	Pindolol may increase the hypotensive activities of Felodipine.	Approved, Investigational
Pioglitazone	The metabolism of Pioglitazone can be decreased when combined with Felodipine.	Approved, Investigational
Pipamperone	The risk or severity of adverse effects can be increased when Pipamperone is combined with Felodipine.	Approved, Investigational
Pirlindole	Pirlindole may increase the hypotensive activities of Felodipine.	Approved
Piroxicam	The metabolism of Piroxicam can be decreased when combined with Felodipine.	Approved, Investigational
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Felodipine.	Approved
Pitolisant	The serum concentration of Pitolisant can be increased when it is combined with Felodipine.	Approved, Investigational
Pivhydrazine	Pivhydrazine may increase the hypotensive activities of Felodipine.	Withdrawn
Platelet Activating Factor	Felodipine may increase the hypotensive activities of Platelet Activating Factor.	Experimental
Polythiazide	Felodipine may increase the hypotensive activities of Polythiazide.	Approved
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Felodipine.	Approved, Investigational
Posaconazole	The metabolism of Felodipine can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Pramipexole	The risk or severity of adverse effects can be increased when Pramipexole is combined with Felodipine.	Approved, Investigational
Pravastatin	The serum concentration of Pravastatin can be increased when it is combined with Felodipine.	Approved
Prazosin	Prazosin may increase the hypotensive activities of Felodipine.	Approved
Primidone	The metabolism of Felodipine can be increased when combined with Primidone.	Approved, Vet Approved
Procarbazine	Procarbazine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Progesterone	The metabolism of Progesterone can be decreased when combined with Felodipine.	Approved, Vet Approved
Propofol	The metabolism of Propofol can be decreased when combined with Felodipine.	Approved, Investigational, Vet Approved
Propranolol	Propranolol may increase the hypotensive activities of Felodipine.	Approved, Investigational
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Felodipine.	Approved
Pyrrolnitrin	The therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Felodipine.	Experimental
Quetiapine	The risk or severity of adverse effects can be increased when Felodipine is combined with Quetiapine.	Approved
Quinapril	Quinapril may increase the hypotensive activities of Felodipine.	Approved, Investigational
Quinidine	The serum concentration of Quinidine can be decreased when it is combined with Felodipine.	Approved, Investigational
Quinine	The metabolism of Quinine can be decreased when combined with Felodipine.	Approved
Radicicol	The therapeutic efficacy of Radicicol can be increased when used in combination with Felodipine.	Experimental
Ramipril	Ramipril may increase the hypotensive activities of Felodipine.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Felodipine.	Approved, Investigational
Rasagiline	Rasagiline may increase the hypotensive activities of Felodipine.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Felodipine.	Approved
Remikiren	Remikiren may increase the hypotensive activities of Felodipine.	Approved
Repaglinide	The metabolism of Repaglinide can be decreased when combined with Felodipine.	Approved, Investigational
Rescinnamine	Felodipine may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	Reserpine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Ribociclib	The serum concentration of Felodipine can be increased when it is combined with Ribociclib.	Approved, Investigational
Rifabutin	The metabolism of Felodipine can be increased when combined with Rifabutin.	Approved, Investigational
Rifampicin	The metabolism of Felodipine can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Felodipine can be increased when combined with Rifapentine.	Approved, Investigational
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Felodipine.	Approved, Investigational
Rilmenidine	Rilmenidine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Rilpivirine	The serum concentration of Rilpivirine can be increased when it is combined with Felodipine.	Approved
Riociguat	The metabolism of Riociguat can be decreased when combined with Felodipine.	Approved
Risperidone	Felodipine may increase the hypotensive activities of Risperidone.	Approved, Investigational
Rituximab	Felodipine may increase the hypotensive activities of Rituximab.	Approved
Rofecoxib	The metabolism of Rofecoxib can be decreased when combined with Felodipine.	Approved, Investigational, Withdrawn
Ropinirole	The risk or severity of adverse effects can be increased when Ropinirole is combined with Felodipine.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Felodipine.	Approved
Rosiglitazone	The metabolism of Rosiglitazone can be decreased when combined with Felodipine.	Approved, Investigational
Rosuvastatin	The serum concentration of Rosuvastatin can be increased when it is combined with Felodipine.	Approved
Rotigotine	The risk or severity of adverse effects can be increased when Rotigotine is combined with Felodipine.	Approved
Rucaparib	The metabolism of Felodipine can be decreased when combined with Rucaparib.	Approved, Investigational
Sacubitril	The risk or severity of adverse effects can be increased when Sacubitril is combined with Felodipine.	Approved
Safrazine	Safrazine may increase the hypotensive activities of Felodipine.	Withdrawn
Salicylhydroxamic Acid	The therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Felodipine.	Experimental
Salicylic acid	The therapeutic efficacy of Salicylic acid can be increased when used in combination with Felodipine.	Approved, Investigational, Vet Approved
Saprisartan	Felodipine may increase the hypotensive activities of Saprisartan.	Experimental
Saquinavir	The metabolism of Felodipine can be decreased when combined with Saquinavir.	Approved, Investigational
Sarilumab	The therapeutic efficacy of Felodipine can be decreased when used in combination with Sarilumab.	Approved, Investigational
Secobarbital	The metabolism of Felodipine can be increased when combined with Secobarbital.	Approved, Vet Approved
Selegiline	Selegiline may increase the hypotensive activities of Felodipine.	Approved, Investigational, Vet Approved
Selexipag	The metabolism of Selexipag can be decreased when combined with Felodipine.	Approved
Seratrodast	The metabolism of Seratrodast can be decreased when combined with Felodipine.	Approved
Sertaconazole	The therapeutic efficacy of Sertaconazole can be increased when used in combination with Felodipine.	Approved, Investigational
Sevoflurane	The risk or severity of adverse effects can be increased when Sevoflurane is combined with Felodipine.	Approved, Vet Approved
Sildenafil	Sildenafil may increase the antihypertensive activities of Felodipine.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Felodipine.	Approved
Siltuximab	The serum concentration of Felodipine can be decreased when it is combined with Siltuximab.	Approved, Investigational
Simeprevir	The serum concentration of Felodipine can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Simvastatin can be increased when it is combined with Felodipine.	Approved
Sinefungin	The therapeutic efficacy of Sinefungin can be increased when used in combination with Felodipine.	Experimental
Sirolimus	The therapeutic efficacy of Sirolimus can be increased when used in combination with Felodipine.	Approved, Investigational
Sitagliptin	The metabolism of Sitagliptin can be decreased when combined with Felodipine.	Approved, Investigational
Sitaxentan	Felodipine may increase the hypotensive activities of Sitaxentan.	Approved, Investigational, Withdrawn
Sorafenib	The metabolism of Sorafenib can be decreased when combined with Felodipine.	Approved, Investigational
Sotalol	The risk or severity of adverse effects can be increased when Sotalol is combined with Felodipine.	Approved
Spirapril	Felodipine may increase the hypotensive activities of Spirapril.	Approved
Spironolactone	The risk or severity of adverse effects can be increased when Spironolactone is combined with Felodipine.	Approved
St. John's Wort	The serum concentration of Felodipine can be decreased when it is combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Stiripentol	The serum concentration of Felodipine can be increased when it is combined with Stiripentol.	Approved
Streptokinase	The risk or severity of adverse effects can be increased when Streptokinase is combined with Felodipine.	Approved, Investigational
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Felodipine.	Approved, Investigational
Sulconazole	The therapeutic efficacy of Sulconazole can be increased when used in combination with Felodipine.	Approved
Sulfadiazine	The metabolism of Sulfadiazine can be decreased when combined with Felodipine.	Approved, Investigational, Vet Approved
Sulfinpyrazone	The metabolism of Sulfinpyrazone can be decreased when combined with Felodipine.	Approved
Sulfisoxazole	The metabolism of Felodipine can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Tacrolimus	The serum concentration of Tacrolimus can be increased when it is combined with Felodipine.	Approved, Investigational
Tadalafil	Tadalafil may increase the antihypertensive activities of Felodipine.	Approved, Investigational
Talinolol	Felodipine may increase the hypotensive activities of Talinolol.	Investigational
Tamsulosin	The risk or severity of hypotension can be increased when Tamsulosin is combined with Felodipine.	Approved, Investigational
Tavaborole	The therapeutic efficacy of Tavaborole can be increased when used in combination with Felodipine.	Approved, Investigational
Tazarotene	The metabolism of Tazarotene can be decreased when combined with Felodipine.	Approved, Investigational
Telaprevir	The metabolism of Felodipine can be decreased when combined with Telaprevir.	Approved, Withdrawn
Telithromycin	The metabolism of Felodipine can be decreased when combined with Telithromycin.	Approved
Telmisartan	Telmisartan may increase the hypotensive activities of Felodipine.	Approved, Investigational
Temazepam	The metabolism of Temazepam can be decreased when combined with Felodipine.	Approved, Investigational
Temocapril	Felodipine may increase the hypotensive activities of Temocapril.	Experimental, Investigational
Terazosin	The risk or severity of hypotension can be increased when Terazosin is combined with Felodipine.	Approved
Terbinafine	The metabolism of Terbinafine can be decreased when combined with Felodipine.	Approved, Investigational, Vet Approved
Terconazole	The therapeutic efficacy of Terconazole can be increased when used in combination with Felodipine.	Approved
Terguride	The risk or severity of adverse effects can be increased when Terguride is combined with Felodipine.	Experimental
Terlipressin	Felodipine may increase the hypotensive activities of Terlipressin.	Approved, Investigational
Testosterone	The metabolism of Testosterone can be decreased when combined with Felodipine.	Approved, Investigational
Testosterone cypionate	The metabolism of Testosterone cypionate can be decreased when combined with Felodipine.	Approved
Testosterone enanthate	The metabolism of Testosterone enanthate can be decreased when combined with Felodipine.	Approved
Testosterone undecanoate	The metabolism of Testosterone undecanoate can be decreased when combined with Felodipine.	Approved, Investigational
Tetrahydropalmatine	Felodipine may increase the hypotensive activities of Tetrahydropalmatine.	Investigational
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Felodipine.	Approved, Investigational, Withdrawn
Theodrenaline	Felodipine may increase the hypotensive activities of Theodrenaline.	Investigational
Theophylline	The metabolism of Theophylline can be decreased when combined with Felodipine.	Approved
Thiamylal	The metabolism of Felodipine can be increased when combined with Thiamylal.	Approved, Vet Approved
Thiopental	The metabolism of Felodipine can be increased when combined with Thiopental.	Approved, Vet Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Felodipine.	Approved, Withdrawn
Thymol	The therapeutic efficacy of Thymol can be increased when used in combination with Felodipine.	Approved
Tibolone	Felodipine may increase the hypotensive activities of Tibolone.	Approved, Investigational
Ticlopidine	The metabolism of Felodipine can be decreased when combined with Ticlopidine.	Approved
Ticrynafen	Felodipine may increase the hypotensive activities of Ticrynafen.	Withdrawn
Timolol	Timolol may increase the hypotensive activities of Felodipine.	Approved
Tioconazole	The therapeutic efficacy of Tioconazole can be increased when used in combination with Felodipine.	Approved
Tizanidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Felodipine.	Approved, Investigational
Tocilizumab	The serum concentration of Felodipine can be decreased when it is combined with Tocilizumab.	Approved
Tolazoline	Tolazoline may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Tolbutamide	The metabolism of Tolbutamide can be decreased when combined with Felodipine.	Approved, Investigational
Tolcapone	The risk or severity of adverse effects can be increased when Tolcapone is combined with Felodipine.	Approved, Withdrawn
Tolciclate	The therapeutic efficacy of Tolciclate can be increased when used in combination with Felodipine.	Experimental
Tolnaftate	The therapeutic efficacy of Tolnaftate can be increased when used in combination with Felodipine.	Approved, Investigational, Vet Approved
Tolonidine	Felodipine may increase the hypotensive activities of Tolonidine.	Experimental
Toloxatone	Toloxatone may increase the hypotensive activities of Felodipine.	Approved
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Felodipine.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Felodipine.	Approved, Investigational
Torasemide	The metabolism of Torasemide can be decreased when combined with Felodipine.	Approved
Trandolapril	Trandolapril may increase the hypotensive activities of Felodipine.	Approved
Tranylcypromine	Tranylcypromine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Travoprost	Travoprost may increase the hypotensive activities of Felodipine.	Approved
Treprostinil	Treprostinil may increase the hypotensive activities of Felodipine.	Approved, Investigational
Tretinoin	The metabolism of Tretinoin can be decreased when combined with Felodipine.	Approved, Investigational, Nutraceutical
Triamterene	The risk or severity of adverse effects can be increased when Triamterene is combined with Felodipine.	Approved
Trichlormethiazide	Trichlormethiazide may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Trimazosin	Trimazosin may increase the hypotensive activities of Felodipine.	Experimental
Trimethadione	The metabolism of Trimethadione can be decreased when combined with Felodipine.	Approved
Trimethaphan	Trimethaphan may increase the hypotensive activities of Felodipine.	Approved, Investigational
Trimethoprim	The metabolism of Trimethoprim can be decreased when combined with Felodipine.	Approved, Vet Approved
Trimetrexate	The therapeutic efficacy of Trimetrexate can be increased when used in combination with Felodipine.	Approved, Investigational
Troglitazone	The metabolism of Troglitazone can be decreased when combined with Felodipine.	Investigational, Withdrawn
Udenafil	Udenafil may increase the antihypertensive activities of Felodipine.	Approved, Investigational
Unoprostone	Felodipine may increase the hypotensive activities of Unoprostone.	Approved, Investigational
Urapidil	Urapidil may increase the hypotensive activities of Felodipine.	Investigational
Valsartan	Valsartan may increase the hypotensive activities of Felodipine.	Approved, Investigational
Vardenafil	Vardenafil may increase the antihypertensive activities of Felodipine.	Approved
Velpatasvir	The metabolism of Velpatasvir can be decreased when combined with Felodipine.	Approved, Investigational
Vemurafenib	The serum concentration of Felodipine can be decreased when it is combined with Vemurafenib.	Approved
Venlafaxine	The metabolism of Felodipine can be decreased when combined with Venlafaxine.	Approved
Verapamil	The metabolism of Felodipine can be decreased when combined with Verapamil.	Approved
Vincamine	Felodipine may increase the hypotensive activities of Vincamine.	Experimental
Vincristine	The excretion of Vincristine can be decreased when combined with Felodipine.	Approved, Investigational
Vinpocetine	Felodipine may increase the hypotensive activities of Vinpocetine.	Investigational
Voriconazole	The metabolism of Felodipine can be decreased when combined with Voriconazole.	Approved, Investigational
Vortioxetine	The metabolism of Vortioxetine can be decreased when combined with Felodipine.	Approved, Investigational
Voxilaprevir	The metabolism of Voxilaprevir can be decreased when combined with Felodipine.	Approved, Investigational
Warfarin	The metabolism of Warfarin can be decreased when combined with Felodipine.	Approved
Xipamide	Felodipine may increase the hypotensive activities of Xipamide.	Experimental
Xylometazoline	Felodipine may increase the hypotensive activities of Xylometazoline.	Approved, Investigational
Yohimbine	Yohimbine may decrease the antihypertensive activities of Felodipine.	Approved, Investigational, Vet Approved
Zafirlukast	The metabolism of Zafirlukast can be decreased when combined with Felodipine.	Approved, Investigational
Zidovudine	The metabolism of Zidovudine can be decreased when combined with Felodipine.	Approved
Ziprasidone	The metabolism of Felodipine can be decreased when combined with Ziprasidone.	Approved
Zofenopril	Felodipine may increase the hypotensive activities of Zofenopril.	Experimental
Zopiclone	The metabolism of Zopiclone can be decreased when combined with Felodipine.	Approved

Food Interactions

• Grapefruit down regulates post-translational expression of CYP3A4, the major metabolizing enzyme of nifedipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of nifedipine and may cause toxicity. Avoid grapefruit products while on this medication.
• Take without regard to meals.

References

Synthesis Reference

Vinay Sharma, "Preparation of micron-size felodipine particles by microfluidization." U.S. Patent US20020086061, issued July 04, 2002.

US20020086061

General References

1. Dunselman PH, Edgar B: Felodipine clinical pharmacokinetics. Clin Pharmacokinet. 1991 Dec;21(6):418-30. [PubMed:1782737]

External Links

Human Metabolome Database

HMDB0015158

KEGG Drug

D00319

PubChem Compound

3333

PubChem Substance

46506968

ChemSpider

3216

BindingDB

189379

ChEBI

585948

ChEMBL

CHEMBL1480

Therapeutic Targets Database

DAP000487

PharmGKB

PA449591

IUPHAR

4190

Guide to Pharmacology

GtP Drug Page

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

PDRhealth

PDRhealth Drug Page

Wikipedia

Felodipine

ATC Codes

C08CA02 — Felodipine

• C08CA — Dihydropyridine derivatives
• C08C — SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
• C08 — CALCIUM CHANNEL BLOCKERS
• C — CARDIOVASCULAR SYSTEM

C09BB05 — Ramipril and felodipine

• C09BB — ACE inhibitors and calcium channel blockers
• C09B — ACE INHIBITORS, COMBINATIONS
• C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C — CARDIOVASCULAR SYSTEM

AHFS Codes

• 24:28.08 — Dihydropyridines

FDA label

Download (228 KB)

MSDS

Download (55.4 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Treatment	Food-Drug Interactions	1
3	Completed	Prevention	Atherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus	1
3	Completed	Treatment	BMI >30 kg/m2 / High Blood Pressure (Hypertension)	1
4	Completed	Prevention	Disorders Related to Lung Transplantation	1
4	Completed	Treatment	High Blood Pressure (Hypertension)	2
4	Completed	Treatment	High Blood Pressure (Hypertension) / Left Ventricular Hypertrophy	1
4	Unknown Status	Treatment	High Blood Pressure (Hypertension) / Sexual Dysfunctions	1
Not Available	Completed	Not Available	Healthy Volunteers	2
Not Available	Completed	Not Available	High Blood Pressure (Hypertension)	1
Not Available	Completed	Treatment	High Blood Pressure (Hypertension)	1
Not Available	Unknown Status	Basic Science	High Blood Pressure (Hypertension) / Insulin Resistance / Microcirculation	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

• A-S Medication Solutions LLC
• AstraZeneca Inc.
• Atlantic Biologicals Corporation
• Bryant Ranch Prepack
• Cardinal Health
• Heartland Repack Services LLC
• Lake Erie Medical and Surgical Supply
• Liberty Pharmaceuticals
• Merck & Co.
• Murfreesboro Pharmaceutical Nursing Supply
• Mutual Pharmaceutical Co.
• Mylan
• Nucare Pharmaceuticals Inc.
• PD-Rx Pharmaceuticals Inc.
• Physicians Total Care Inc.
• Preferred Pharmaceuticals Inc.
• Prepackage Specialists
• Prepak Systems Inc.
• Prescript Pharmaceuticals
• Ranbaxy Laboratories
• Resource Optimization and Innovation LLC
• Richmond Pharmacy
• Sandhills Packaging Inc.
• UDL Laboratories
• Va Cmop Dallas
• Vangard Labs Inc.

Dosage forms

Form	Route	Strength
Tablet	Oral
Tablet, film coated	Oral	2.5 mg/1
Tablet, film coated, extended release	Oral	10 mg/1
Tablet, film coated, extended release	Oral	2.5 mg/1
Tablet, film coated, extended release	Oral	5 mg/1
Tablet, extended release	Oral	10 mg/1
Tablet, extended release	Oral	2.5 mg/1
Tablet, extended release	Oral	5 mg/1
Tablet, extended release	Oral	10 mg
Tablet, extended release	Oral	2.5 mg
Tablet, extended release	Oral	5 mg

Prices

Unit description	Cost	Unit
Plendil 10 mg 24 Hour tablet	3.17USD	tablet
Plendil er 10 mg tablet	3.05USD	tablet
Plendil 10 mg tablet sa	2.96USD	tablet
Felodipine 10 mg 24 Hour tablet	2.95USD	tablet
Plendil er 2.5 mg tablet	2.94USD	tablet
Felodipine er 10 mg tablet	2.72USD	tablet
Plendil er 5 mg tablet	2.6USD	tablet
Plendil 5 mg 24 Hour tablet	1.77USD	tablet
Plendil 2.5 mg 24 Hour tablet	1.76USD	tablet
Felodipine 5 mg 24 Hour tablet	1.67USD	tablet
Plendil 2.5 mg tablet sa	1.65USD	tablet
Plendil 5 mg tablet sa	1.65USD	tablet
Felodipine 2.5 mg 24 Hour tablet	1.57USD	tablet
Felodipine er 2.5 mg tablet	1.51USD	tablet
Felodipine er 5 mg tablet	1.51USD	tablet
Renedil 10 mg Extended-Release Tablet	1.22USD	tablet
Plendil 10 mg Extended-Release Tablet	1.15USD	tablet
Renedil 5 mg Extended-Release Tablet	0.81USD	tablet
Plendil 5 mg Extended-Release Tablet	0.77USD	tablet
Sandoz Felodipine 10 mg Extended-Release Tablet	0.73USD	tablet
Renedil 2.5 mg Extended-Release Tablet	0.6USD	tablet
Plendil 2.5 mg Extended-Release Tablet	0.57USD	tablet
Sandoz Felodipine 5 mg Extended-Release Tablet	0.48USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	145 °C	Not Available
water solubility	19.7 mg/L	Not Available
logP	3.86	SANGSTER (1994)
Caco2 permeability	-4.64	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	0.00715 mg/mL	ALOGPS
logP	4.36	ALOGPS
logP	3.44	ChemAxon
logS	-4.7	ALOGPS
pKa (Strongest Basic)	5.39	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	64.63 Å2	ChemAxon
Rotatable Bond Count	6	ChemAxon
Refractivity	99.2 m3·mol-1	ChemAxon
Polarizability	38.04 Å3	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9878
Blood Brain Barrier	-	0.83
Caco-2 permeable	+	0.8867
P-glycoprotein substrate	Substrate	0.5149
P-glycoprotein inhibitor I	Inhibitor	0.8563
P-glycoprotein inhibitor II	Non-inhibitor	0.8383
Renal organic cation transporter	Non-inhibitor	0.8664
CYP450 2C9 substrate	Non-substrate	0.8357
CYP450 2D6 substrate	Non-substrate	0.9116
CYP450 3A4 substrate	Substrate	0.6954
CYP450 1A2 substrate	Inhibitor	0.9106
CYP450 2C9 inhibitor	Inhibitor	0.8948
CYP450 2D6 inhibitor	Non-inhibitor	0.9232
CYP450 2C19 inhibitor	Inhibitor	0.8994
CYP450 3A4 inhibitor	Inhibitor	0.7959
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.9304
Ames test	Non AMES toxic	0.7849
Carcinogenicity	Non-carcinogens	0.7511
Biodegradation	Not ready biodegradable	0.9527
Rat acute toxicity	2.4526 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9455
hERG inhibition (predictor II)	Non-inhibitor	0.8734

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0udu-0139000000-085071c20c5d0c134d8f

Taxonomy

Description

This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Pyridines and derivatives

Sub Class

Hydropyridines

Direct Parent

Dihydropyridinecarboxylic acids and derivatives

Alternative Parents

Dichlorobenzenes / Dicarboxylic acids and derivatives / Aryl chlorides / Vinylogous amides / Methyl esters / Enoate esters / Amino acids and derivatives / Enamines / Dialkylamines / Azacyclic compoundsOrganopnictogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds

show 5 more

Substituents

Dihydropyridinecarboxylic acid derivative / 1,2-dichlorobenzene / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Vinylogous amideAlpha,beta-unsaturated carboxylic ester / Enoate ester / Methyl ester / Amino acid or derivatives / Carboxylic acid ester / Carboxylic acid derivative / Secondary aliphatic amine / Enamine / Secondary amine / Azacycle / Organonitrogen compound / Hydrocarbon derivative / Organooxygen compound / Organic oxide / Amine / Organohalogen compound / Carbonyl group / Organopnictogen compound / Organic oxygen compound / Organic nitrogen compound / Organochloride / Aromatic heteromonocyclic compound

show 22 more

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

ethyl ester, dichlorobenzene, methyl ester, dihydropyridine (CHEBI:585948)

Drug created on June 13, 2005 07:24 / Updated on April 17, 2018 01:03